Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEALEY ALS Platform Trial - Regimen I NUZ-001
NCT07410806Phase 3Active, not recruiting
- Start
- Feb 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing NUZ-001 with Matching Placebo (2 arms). Primary endpoint: Disease Progression at 36 weeks. Started Feb 2026; status: active, not recruiting.
02
Drugs
monepantel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07410806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410806.